General Information
| Application | Inhibitor |
|---|
| Description | Iniparib (BSI-201) is an antineoplastic originally thought to be a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor. Recent studies indicate Iniparib is not a PARP-1 inhibitor, and its mechanism of action is currently unknown. |
|---|
| Cas NO. | 160003-66-7 |
|---|
| Purity | ≥98% |
|---|---|
| Molecular Weight | 292.03 |
| Formula | C7H5IN2O3 |
| Solubility |
DMSO : ≥56 mg/mL Ethanol : ≥35 mg/mL Water : ≥1.2 mg/mL |
|---|
| Alias | BSI-201;Iniparib; NSC-746045; IND-71677; BSI 201; BSI201;4-Iodo-3-nitrobenzamide |
|---|
| Target / IC50 |
PARP1 |
|---|
| Storage |
Powder : -20°C for 3 years |
|---|
|
|
1 mg |
5 mg |
10 mg |
|
|
1 mM |
3.4243 mL | 17.1215 mL | 34.2431 mL | |
| 5 mM | 0.6849 mL | 3.4243 mL | 6.8486 mL | |
| 10 mM | 0.3424 mL | 1.7122 mL | 3.4243 mL | |
.png)